Right heart function in PAH improves with investigational oral therapy CS1
Three months of CS1 therapy boosted quality of life, while symptoms tied to heart failure and clinical worsening and mortality risk declined.| Pulmonary Hypertension News
Three months of CS1 therapy boosted quality of life, while symptoms tied to heart failure and clinical worsening and mortality risk declined.| Pulmonary Hypertension News
Cereno's expanded access program for investigational therapy CS1 covers 10 PAH patients, following a Phase 2a clinical trial.| Pulmonary Hypertension News
The investigational therapy CS1 led to beneficial changes in for people with pulmonary arterial hypertension in a Phase 2a clinical trial.| Pulmonary Hypertension News
Cereno Scientific reported a successful meeting with the FDA on the design of a future clinical trial for its PAH therapy candidate CS1.| Pulmonary Hypertension News
